Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Insights

Medifast's Q4 2024 results paint a concerning picture of a company in transition, grappling with the disruptive impact of GLP-1 medications on the traditional weight loss industry. The 37.7% revenue decline and sharp reduction in active coaches signal a fundamental challenge to the company's coach-centric business model.

The financial metrics reveal several critical insights:

The company's market capitalization of $177.3 million is now only slightly higher than its cash position of $162.3 million, suggesting the market is significantly discounting the underlying business value
Despite the revenue decline, maintenance of a 74.1% gross margin indicates pricing power and cost control in core operations
The Q1 2025 guidance of $100-120 million revenue with potential losses up to $0.50 per share suggests continued near-term pressure

The company's strategic pivot to incorporate GLP-1 medications through the LifeMD partnership represents an attempt to stay relevant, but the transition period is proving challenging. The 5.5% decline in revenue per coach indicates difficulties in customer acquisition and retention, likely due to competition from pharmaceutical weight loss solutions.

While the strong balance sheet provides a safety net for transformation, the company's ability to stabilize and grow in a GLP-1-dominated market remains uncertain. The focus on marketing spend (550 basis points increase) suggests aggressive efforts to reposition the brand, but the effectiveness of these investments is yet to be proven.

02/18/2025 - 04:05 PM

BALTIMORE--(BUSINESS WIRE)-- Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024.

Fourth Quarter 2024

Revenue of $119.0 million, with revenue per active earning coach of $4,391
Independent active earning OPTAVIA coaches of 27,100
Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million)
Earnings per diluted share ("EPS") of $0.07 (non-GAAP adjusted EPS of $0.10)
Cash, Cash Equivalents, and Investment Securities of $162.3 million and no debt

Full Year 2024

Revenue of $602.5 million
Net income of $2.1 million (non-GAAP adjusted net income of $20.2 million)
EPS of $0.19 (non-GAAP adjusted EPS of $1.84)

“This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO.

“Throughout the year, our team has shown resilience and adaptability as we navigated evolving market dynamics, enabling Medifast to remain positioned to be a leader in health and wellness in a GLP-1 world. We're committed to offering solutions that meet the diverse needs of our customers, whether they are focusing solely on our habit-based approach to weight loss, using GLP-1 medications, or transitioning off them.”

Chard continued, “As we look ahead, our top priorities center on reestablishing growth across all of our key metrics, including driving coach productivity through accelerated customer acquisition, and expanding the number of active earning coaches. These efforts should allow us to broaden our reach, restore revenue and profitability growth and deliver long-term value to all our stakeholders.”

Fourth Quarter 2024 Results

Fourth quarter 2024 revenue decreased 37.7% to $119.0 million from $191.0 million for the fourth quarter of 2023 primarily driven by a decrease in the number of active earning OPTAVIA coaches and lower coach productivity. The total number of active earning OPTAVIA coaches decreased 34.1% to 27,100 compared to 41,100 for the fourth quarter of 2023. The average revenue per active earning OPTAVIA coach was $4,391, compared to $4,648 for the fourth quarter last year, a decline of 5.5% primarily driven by continued pressure on customer acquisition.

Gross profit decreased 37.6% to $88.2 million from $141.4 million for the fourth quarter of 2023. The decrease in gross profit was due to lower sales volumes. The company’s gross profit as a percentage of revenue was 74.1% compared to 74.0% in the fourth quarter of 2023.

Selling, general, and administrative expenses (“SG&A”) decreased 34.1% to $87.5 million compared to $132.7 million for the fourth quarter of 2023. The decrease in SG&A was primarily due to a $27.4 million decrease in OPTAVIA coach compensation, a $7.1 million decrease in employee compensation, a $5.8 million decrease due to non-recurring costs incurred in the fourth quarter of 2023 to establish the company's medically supported weight loss initiative, which includes collaboration costs with LifeMD, and a $3.0 million decrease in costs for coach-related events, partially offset by $6.5 million of costs for company led marketing efforts. As a percentage of revenue, SG&A increased 400 basis points year-over-year to 73.5% of revenue, as compared to 69.5% for the fourth quarter of 2023. The increase in SG&A as a percentage of revenue was primarily due to 550 basis points of company led marketing spend and 210 basis points of loss of leverage on fixed costs, partially offset by a 300 basis point decrease due to non-recurring costs incurred in the fourth quarter of 2023 to establish the company's medically supported weight loss initiative, as well as a 100 basis point decrease for costs related to coach-related events. On a non-GAAP adjusted basis, which excludes non-GAAP adjustments in the prior comparable period for IT and supply chain optimization and the LifeMD collaboration costs, SG&A decreased 30.1% to $87.5 million and non-GAAP adjusted SG&A moved 800 basis points higher as a percentage of revenue to 73.5%.

Income from operations decreased 91.8% to $0.7 million from $8.7 million in the prior year period. As a percentage of revenue, income from operations was 0.6% for the fourth quarter of 2024 compared to 4.5% in the prior-year period due to the factors described above impacting revenue and SG&A expenses. Non-GAAP adjusted income from operations as a percentage of revenue was 0.6%, a decrease of 790 basis points from the year-ago period.

Other income decreased 49.7% to $0.6 million from $1.1 million for the fourth quarter of 2023. The decrease in other income was primarily due to unrealized losses on the investment in LifeMD common stock. Non-GAAP other income, which excludes the quarter's unrealized losses on LifeMD common stock investment, decreased 18.2% to $0.9 million primarily due to the write-off of unamortized debt issuance costs.

The effective tax rate was 37.3% for the fourth quarter of 2024 compared to 38.4% in the prior-year period. The non-GAAP effective tax rate was 34.6% as compared to 31.6% in the prior year period.

In the fourth quarter of 2024, net income was $0.8 million, or $0.07 per diluted share, based on approximately 11.0 million shares of common stock outstanding. In the fourth quarter of 2023, net income was $6.0 million, or $0.55 per diluted share, based on approximately 10.9 million shares of common stock outstanding. In the fourth quarter of 2024, non-GAAP adjusted net income was $1.1 million, or $0.10 per diluted share, compared to non-GAAP adjusted net income of $11.9 million, or $1.09 per diluted share, in the year-ago period.

Full Year Fiscal 2024 Results

For the fiscal year ended December 31, 2024, revenue decreased 43.8% to $602.5 million compared to revenue of $1.1 billion in 2023. Net income for 2024 was $2.1 million, or $0.19 per diluted share, based on approximately 11.0 million shares outstanding. This compares to 2023 net income of $99.4 million, or $9.10 per diluted share, based on approximately 10.9 million shares outstanding. On a non-GAAP adjusted basis, net income decreased 80.8% to $20.2 million and EPS decreased 80.9% to $1.84 per diluted share, compared to the prior year period’s adjusted EPS of $9.64 per diluted share.

Capital Allocation and Balance Sheet

The company’s balance sheet remains strong with cash, cash equivalents, and investment securities of $162.3 million and no interest-bearing debt as of December 31, 2024, compared to $150.0 million in cash and cash equivalents and no debt at December 31, 2023.

Outlook

The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share. The EPS range excludes any gains or losses from changes in market price of the company's LifeMD common stock investment.

Conference Call Information

The conference call is scheduled for today, Tuesday, February 18, 2025 at 4:30 PM ET. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast’s website at www.MedifastInc.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1705513&tp_key=7b87c842ba and will be archived online and available through May 18, 2025. In addition, listeners may dial (201) 389-0879 to join via telephone. A telephonic playback will be available from February 18, 2025 at 8:30 PM ET through Tuesday, February 25, 2025 at 11:59 PM ET. Participants can dial (412) 317-6671 and enter passcode 13751326 to hear the playback.

About Medifast^®:

Medifast (NYSE: MED) is the 40+ year old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. Through the company's collaboration with national virtual primary care provider LifeMD® (Nasdaq: LFMD) and its affiliated medical group, customers now have access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature™. Visit MedifastInc.com and OPTAVIA.com for more information and follow @Medifast on X and LinkedIn.

MED-F

Forward-Looking Statements

Please Note: This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” “anticipate,” “expect” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast’s objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Medifast's inability to maintain and grow the network of independent OPTAVIA coaches; industry competition and new weight loss products, including weight loss medications such as GLP-1s, or services; Medifast’s health or advertising related claims by OPTAVIA customers; Medifast's inability to continue to develop new products; effectiveness of Medifast's advertising and marketing programs, including use of social media by OPTAVIA coaches; the departure of one or more key personnel; Medifast's inability to protect against online security risks and cyberattacks; risks associated with Medifast's direct-to-consumer business model; disruptions in Medifast's supply chain; product liability claims; Medifast's planned growth into domestic markets including through its collaboration with LifeMD, Inc.; adverse publicity associated with Medifast's products; the impact of existing and future laws and regulations on Medifast’s business; fluctuations of Medifast's common stock market price; increases in litigation; actions of activist investors; the consequences of other geopolitical events, overall economic and market conditions and the resulting impact on consumer sentiment and spending patterns; and Medifast's ability to prevent or detect a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.


MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(U.S. dollars in thousands, except per share amounts & dividend data)

	Three months ended December 31,						Year ended December 31,
	2024			2023			2024			2023

Revenue	$	119,003		$	191,015		$	602,463		$	1,072,054
Cost of sales		30,784			49,646			157,840			296,204
Gross profit		88,219			141,369			444,623			775,850

Selling, general, and administrative		87,510			132,693			441,745			649,448

Income from operations		709			8,676			2,878			126,402

Other income
Interest income		953			1,176			4,804			2,490
Other expense		(387	)		(50	)		(3,895	)		(95	)
		566			1,126			909			2,395

Income before provision for income taxes		1,275			9,802			3,787			128,797

Provision for income taxes		475			3,766			1,696			29,382

Net income	$	800		$	6,036		$	2,091		$	99,415

Earnings per share - basic	$	0.07		$	0.55		$	0.19		$	9.13

Earnings per share - diluted	$	0.07		$	0.55		$	0.19		$	9.10

Weighted average shares outstanding
Basic		10,938			10,893			10,930			10,884
Diluted		10,983			10,935			10,963			10,921

Cash dividends declared per share	$	—		$	—		$	—		$	4.95


MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(U.S. dollars in thousands, except par value)

	December 31, 2024		December 31, 2023
ASSETS
Current Assets
Cash and cash equivalents	$	90,928	$	94,440
Inventories, net		42,421		54,591
Investments		71,416		55,601
Income taxes, prepaid		—		8,727
Prepaid expenses and other current assets		9,639		10,670
Total current assets		214,404		224,029

Property, plant and equipment - net of accumulated depreciation		37,527		51,467
Right-of-use assets		11,155		15,645
Other assets		9,667		14,650
Deferred tax assets, net		11,460		4,117

TOTAL ASSETS	$	284,213	$	309,908

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued expenses	$	56,494	$	86,415
Income taxes payable		1,485		—
Current lease obligations		6,182		5,885
Total current liabilities		64,161		92,300

Lease obligations, net of current lease obligations		9,943		16,127
Total liabilities		74,104		108,427

Commitments

Stockholders' Equity
Common stock, par value 0.001 per share: 20,000 shares authorized;
10,938 and 10,896 issued and outstanding
at December 31, 2024 and December 31, 2023		11		11
Additional paid-in capital		33,136		26,573
Accumulated other comprehensive income		180		248
Retained earnings		176,782		174,649
Total stockholders' equity		210,109		201,481

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	284,213	$	309,908

Non-GAAP Financial Measures

In an effort to provide investors with additional information regarding results, the company discloses various non-GAAP financial measures in the quarterly earnings press release and other public disclosures. The following GAAP financial measures have been presented on an as adjusted basis: cost of sales, gross profit, SG&A expenses, income from operations, other income, provision for income taxes, net income, effective tax rate, and diluted earnings per share. Each of these non-GAAP financial measures excludes the impact of certain amounts as further identified below that the company believes are not indicative of its core ongoing operational performance. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included below. These non-GAAP financial measures are not intended to replace GAAP financial measures.

These non-GAAP financial measures are used internally to evaluate and manage the company's operations because the company believes they provide useful supplemental information regarding the company's on-going economic performance. The company has chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results and as a means to emphasize the results of on-going operations.

The following tables reconcile the non-GAAP financial measures included in this release:

	Three months ended December 31, 2024
	GAAP		Unrealized Loss on Investment in LifeMD Common Stock		Non-GAAP
Cost of sales	$	30,784	$	—	$	30,784
Gross profit		88,219		—		88,219
Selling, general, and administrative		87,510		—		87,510
Income from operations		709		—		709
Other income		566		355		921
Provision for income taxes		475		89		564
Net income		800		266		1,066
Diluted earnings per share ⁽¹⁾		0.07		0.02		0.10

	Three months ended December 31, 2023
	GAAP		IT and Supply Chain Optimization			LifeMD Collaboration Costs			Non-GAAP
Cost of sales	$	49,646	$	—		$	—		$	49,646
Gross profit		141,369		—			—			141,369
Selling, general, and administrative		132,693		(2,555	)		(5,000	)		125,138
Income from operations		8,676		2,555			5,000			16,231
Other income		1,126		—			—			1,126
Provision for income taxes		3,766		583			1,141			5,490
Net income		6,036		1,972			3,859			11,867
Diluted earnings per share ⁽¹⁾		0.55		0.18			0.35			1.09

	Year ended December 31, 2024
	GAAP		Supply Chain Optimization and Restructuring of External Manufacturing Agreements			Unrealized Loss on Investment in LifeMD Common Stock		LifeMD Collaboration Costs			Non-GAAP
Cost of sales	$	157,840	$	(2,579	)	$	—	$	—		$	155,261
Gross profit		444,623		2,579			—		—			447,202
Selling, general, and administrative		441,745		(12,502	)		—		(5,000	)		424,243
Income from operations		2,878		15,081			—		5,000			22,959
Other income		909		—			4,089		—			4,998
Provision for income taxes		1,696		3,770			1,022		1,250			7,738
Net income		2,091		11,311			3,067		3,750			20,219
Diluted earnings per share ⁽¹⁾		0.19		1.03			0.28		0.34			1.84

	Year ended December 31, 2023
	GAAP		IT and Supply Chain Optimization			LifeMD Collaboration Costs			Non-GAAP
Cost of sales	$	296,204	$	—		$	—		$	296,204
Gross profit		775,850		—			—			775,850
Selling, general, and administrative		649,448		(2,555	)		(5,000	)		641,893
Income from operations		126,402		2,555			5,000			133,957
Other income		2,395		—			—			2,395
Provision for income taxes		29,382		583			1,141			31,106
Net income		99,415		1,972			3,859			105,246
Diluted earnings per share ⁽¹⁾		9.10		0.18			0.35			9.64

(1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218029135/en/

Investor Contact:

Medifast, Inc.

Steven Zenker

InvestorRelations@medifastinc.com

(443) 379-5256

Source: Medifast

FAQ

What was Medifast's (MED) revenue decline in Q4 2024?

Medifast's Q4 2024 revenue declined 37.7% year-over-year to $119.0 million from $191.0 million in Q4 2023.

How many active OPTAVIA coaches did Medifast (MED) have in Q4 2024?

Medifast had 27,100 active OPTAVIA coaches in Q4 2024, representing a 34.1% decrease from 41,100 coaches in Q4 2023.

What is Medifast's (MED) financial guidance for Q1 2025?

Medifast expects Q1 2025 revenue between $100-120 million and EPS ranging from a loss of $0.50 to $0.00 per share.

What was Medifast's (MED) cash position at the end of 2024?

Medifast had $162.3 million in cash, cash equivalents, and investment securities with no debt as of December 31, 2024.

How much did Medifast's (MED) revenue per active coach decline in Q4 2024?

Revenue per active OPTAVIA coach declined 5.5% to $4,391 in Q4 2024 compared to $4,648 in Q4 2023.

Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

Insights

FAQ

What was Medifast's (MED) revenue decline in Q4 2024?

How many active OPTAVIA coaches did Medifast (MED) have in Q4 2024?

What is Medifast's (MED) financial guidance for Q1 2025?

What was Medifast's (MED) cash position at the end of 2024?

How much did Medifast's (MED) revenue per active coach decline in Q4 2024?

NYSE:MED

MED Rankings

MED Latest News

MED Stock Data

Trending News

Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

Insights

Financial Analyst negative

FAQ

What was Medifast's (MED) revenue decline in Q4 2024?

How many active OPTAVIA coaches did Medifast (MED) have in Q4 2024?

What is Medifast's (MED) financial guidance for Q1 2025?

What was Medifast's (MED) cash position at the end of 2024?

How much did Medifast's (MED) revenue per active coach decline in Q4 2024?

NYSE:MED

MED Rankings

MED Latest News

MED Stock Data